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2DSWE -  two-dimensional shear-wave elastography  
ARFI -  acoustic radiation force impulse 
AUROC -  area under the receiver operating characteristic curve 
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Ultrasound (US) is usually the first and most commonly used tool in the diagnostic 
algorithm for liver disease. It is widely available, non-invasive and offers a real-time 
assessment of the liver in several anatomic planes, using different US modalities such 
as greyscale imaging, Doppler, elastography and contrast-enhanced ultrasound. This 
multiparametric ultrasound (MPUS) provides more information of the examined 
structures and allows for a faster and more accurate diagnosis, usually at the point-of-
care, thus reducing the requirement for some invasive and more expensive methods.  
Current data on the MPUS in hepatology are summarized in this review, mostly 
focused on its use for non-invasive staging of liver fibrosis, detection and classification 
of portal hypertension and oesophageal varices, prognosis in chronic liver diseases 
and characterisation of focal liver lesions (FLL). Based on the available data we 
propose practical algorithms for clinical use of MPUS in chronic liver disease and FLL.   
 








 Multiparametric liver ultrasound (MPUS) is used to assess aetiology, stage, 
complications and prognosis of patients with chronic and some acute liver 
diseases, as well as to characterize focal liver lesions (FLL). 
 Greyscale ultrasound provides morphological informations: presence of the signs 
of cirrhosis, steatosis, portal hypertension (highly specific, but with modest 
sensitivity) and FLL (good sensitivity, lower specificity). 
 Doppler is very useful to assess the aetiology of portal hypertension. 
 Elastography allows for non-invasive staging of liver fibrosis, ruling-out high-risk 
oesophageal varices, prognostication and characterisation of FLL. 
 Contrast enhanced ultrasound is highly (≥90%) accurate to differentiate benign 





1. Introduction  
Ultrasound (US) is usually among the first and most commonly used diagnostic tools 
in the diagnostic algorithm for liver disease. It is widely available, non-invasive, 
harmless, relatively inexpensive and offers a real-time assessment of the liver, on 
several tomographic planes, using different US imaging modalities because of which, 
the term multiparametric US has been introduced [1]. Whereas modalities such as 
greyscale (B-mode) imaging and Doppler are available on all US machines, newer and 
more sophisticated devices offer the additional option of elastography and contrast-
enhanced ultrasound (CEUS). By using various imaging modalities, a multidimensional 
view of the structure of interest is provided and more information is obtained, which 
increases the diagnostic reliability and allows for a faster and more accurate diagnosis, 
usually at the point-of-care (Figure 1). This simplifies and shortens the duration of the 
diagnostic algorithm as other potentially harmful (such as CT and/or liver biopsy) and 
usually long-waiting procedures (MRI) can be avoided, eventually leading to savings 
and the greater availability of diagnostic methods for patients who really need them. 
2. Greyscale (B-mode) ultrasound of the liver 
This is a classical mode of US imaging used to analyse the morphology of the liver and 
other abdominal organs. This method estimates the shape, size, contours and 
parenchymal structure, as well as the presence of focal lesion in the liver. 
Morphological changes to the liver’s vascular system (vessel diameter, patency, the 
presence of solid intraluminal lesions, neoplastic infiltrations/thrombosis) and biliary 
tree (dilation and/or strictures of the bile ducts) can also be assessed. This allows for 
an early differentiation of the cause of the liver lesion as due to cholestatic disease 
(dilatation of the biliary tree), infiltrative disease (focal liver lesions) or parenchymal 
disease (if none of the above is present) and vascular changes can be seen, such as 
thrombosis of the portal vein or of the hepatic veins. US is usually the first method used 
to detect liver tumours but lacks specificity since it is often not easy to characterize a 
liver tumour on the basis of B-mode imaging alone. The clinical background is 
important in this respect since the pre-test probability of having a malignant tumour is 
completely different in patients with underlying cirrhosis or known/suspected malignant 
disease, as opposed to the incidental finding of a focal liver lesion in an otherwise 
healthy liver and individual. US has been recommended as the screening tool  for 
hepatocellular carcinoma (HCC) in patients with cirrhosis, with a reported pooled 
sensitivity of 94% for any stage, but  less impressive 63% sensitivity for early stage 
HCC [2]. In cases of parenchymal disease, further attempts should be directed towards 
defining the stage of liver disease, which refers mostly to being able to rule-in the 
morphological features of cirrhosis: coarse and more echogenic parenchyma, rounded 
edges, nodular external borders and the interface of hepatic veins and hypertrophy of 
the caudate lobe [3,4]. However, one should be aware that US has a low sensitivity 
and a high specificity for cirrhosis in patients with a chronic liver disease, meaning that 
the absence of typical morphological features does not exclude the presence of 
cirrhosis, whereas their presence is highly specific in this clinical setting [5]. US can be 
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used to detect a fatty liver when >20% of the hepatocytes have been fatty transformed 
and the liver then becomes more echogenic (brighter) as compared to the right kidney 
cortex [6]. Several scoring systems have been used to semi-quantitatively assess the 
severity of steatosis based on US imaging [7], whereas newer technological solutions 
enable more precise quantitative assessments of steatosis [8,9].  
US examinations of other abdominal organs may provide additional information that is 
useful to a comprehensive assessment of liver disease. Morphological features of the 
spleen are of major interest since it is enlarged in most cases of cirrhosis. Ascites 
resulting from cirrhosis decompensation can also be found (bearing in mind that ascites 
is not exclusively present in cirrhotic patients, but it may also occur in partients with 
peritoneal carcinomatosis and otherwise healthy liver). In portal hypertension 
secondary to cirrhosis portal vein becomes dilated (>12.5–13 mm), as does the splenic 
vein, coupled with the loss of the respiratory variation in diameter [5]. Hepatic veins 
become narrower with an irregular interface due to the nodular transformation of the 
surrounding liver parenchyma. The progressively increased arterial blood supply to the 
liver is mirrored by the dilated hepatic artery (>3 mm). Colateral porto-systemic 
pathways may be detected as well such as recanalized paraumbilical vein, dilated left 
gastric vein or collateral vessels in the splenic hilum (the later sometimes form spleno-
renal shunt) [10].  
3. Doppler of the hepato-portal system 
The haemodynamic assessment of hepatic portal circulation using Doppler US 
provides valuable information regarding the stage of liver disease as well as the 
potential cause of portal hypertension (PH). In typical cases of cirrhosis, one can 
observe a decreased mean velocity in the portal vein (<15 cm/s) [11] with an increase 
in the resistive index of the hepatic artery (RI>0.7)[12]. At the same time, the spectral 
analysis of the hepatic veins reveals decrease in blood flow pulsatility, i.e., the 
dampening of the triphasic Doppler waveform pattern to biphasic and even 
monophasic. These changes reflect an increase in liver stiffness as a consequence of 
fibrous tissue accumulation and the architectural remodelling of the liver, which also 
leads to increased resistance to blood flow through the liver and the formation of 
arteriovenous and veno-venous intraparenchymal shunts [13]. In advanced stages of 
cirrhosis, a reversal of the portal flow direction occurs from hepatopetal to hepatofugal. 
This sign is not frequently observed but is highly specific to severe liver cirrhosis and 
portal hypertension in the context of chronic liver disease. Again, the presence of these 
signs is highly specific, but their absence may not be used to reliably rule-out PH [10]. 
The concept of liver cirrhosis as a procoagulant condition has been well appreciated 
in recent years as it has become evident that the incidence of portal vein thrombosis 
increases with the deterioration of the liver function observed with the highest 
frequency among patients on the waiting list for transplantation. Portal vein thrombosis 
is readily diagnosed using Doppler US upon demonstration of echogenic material in 
the portal vein lumen, along with the absence of blood flow. One should be mindful of 
the Doppler angle since, in cases where US waves are vertical to the longitudinal axis 
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of the portal vein (which also applies to all other blood vessels), a false absence of 
blood flow may be observed. A long-standing thrombosis may result in the formation 
of a cavernoma, which usually engulfs the extrahepatic biliary ducts [14]. Important 
changes occur in the splenic circulation as the result of splenic congestion and 
histological remodelling, leading to the increased resistance to the arterial inflow, which 
is reflected in the increased resistive and pulsatility indices (RI>0.6 and PI>1) of the 
intraparenchymal branches of the splenic artery [15,16].  
4. Liver elastography 
This modality has been available for the last 15 years and operates through measuring 
the liver stiffness [17]. The hallmark of a chronic liver disease is the accumulation of 
the fibrous tissue that makes the liver stiffer. Therefore, a healthy liver is soft, whereas 
a cirrhotic liver is stiff. In turn, it is possible to determine the stage of the liver fibrosis 
by measuring the liver stiffness and, thus, avoiding a liver biopsy [18]. The basic 
principle of elastography is that a mechanical (compressive) or an enforced acoustic 
impulse that passes through the liver tissue acts as a wavefront that causes minimal 
displacement of the tissue. This leads to the formation of shear waves in the liver 
tissue, which spread faster in a stiff medium (i.e., fibrotic liver). There are several types 
of US elastography [19] that differ in terms of the technological solutions applied and 
the final output they provide. The basic classification is that of qualitative or strain 
elastography and quantitative elastography or elastometry. Qualitative elastography 
assesses only the relative liver stiffness based on the difference in tissue deformation 
using mechanical compression  and therefore it is difficult to make comparisons 
between patients. This is the reason why this method has not been widely accepted 
by the hepatology community for the assessment of fibrosis. All other methods are 
quantitative and based on the measurement of the velocity of shear waves. These may 
be further classified based on whether they use mechanical or US probes to transmit 
exciting impulses into the liver, whether they provide underlying greyscale images of 
the liver and whether elasticity imaging is also provided (Table 1) [19]. The first method 
introduced into clinical practice, and probably the most popular, is transient 
elastography (TE), known under the commercial name of Fibroscan. [17]. This is a 
mono-dimensional method in which a simultaneous US representation of the 
investigated tissue (liver/spleen) cannot be obtained. Other methods have integrated 
the elastography module into the conventional abdominal probes. This enables a 
morphological analysis of the organ in the greyscale with a superimposed measuring 
box in which the liver stiffness is measured. In point shear wave elastography (pSWE), 
the measuring box is small in size and there is no visible elastogram. If the measuring 
box is larger and has a visible elastogram (every point in the elastogram is colour-
coded and represents different shear wave speeds), the method is called two-
dimensional shear wave elastography (2DSWE). 





In order to avoid unreliable results it is recommended to repeat several measurements 
from the same spot and to calculate median value, standard deviation and interquartile 
range (IQR). Ten measurements from the same area are recommended for the 
Fibroscan and pSWE, whereas three to five measurements are recommended for the 
2DSWE. Generally, measurements with IQR/median<30% are considered reliable 
[20]. Elastographic measurements are performed through intercostal spaces over the 
anterior part of the right liver lobe to avoid transmission of the compression by the US 
probe, in a neutral position of breathing and while the patient suspends their breathing 
for three to four seconds. Other conditions besides fibrosis can increase liver stiffness 
(such as liver congestion in right-sided heart failure, cholestasis, severe liver 
inflammation with liver infiltrated by inflammatory cells and tissue oedema, infiltration 
by other cells/compounds such as tumours, amyloidosis, etc.), leading to the 
overestimation of the fibrosis stage. In overweight patients there is an increase in the 
distance between the skin surface, i.e., the probe, and the liver. Consequently, the 
transmission of the exciting impulse and the analysis of the shear waves is more 
difficult, leading to an unreliable or even a failed liver stiffness measurement (LSM). 
This limitation has led to the development of a special probe for the Fibroscan that has 
a deeper penetration (XL probe) and enables more reliable LSM in overweight patients 
(especially with regard to the skin to liver capsule distance (SCD)≥25 mm).  






























































1. Staging of liver fibrosis 
2. Establishing the diagnosis of clinically significant portal hypertension (CSPH) 
and high-risk oesophageal varices (HRV) 
3. Characterization of liver tumours 
4. Prognosis of the clinical outcomes for chronic liver disease. 
4.1.  Staging of liver fibrosis 
Most data have been accumulated using TE and several meta-analyses results of the 
cut-off values and the diagnostic performance of the method used to differentiate 
between the stages of liver fibrosis. Accordingly, the area that is below the receiver 
operating curves (AUROC) for significant fibrosis (F≥2 according to the METAVIR 
classification) is 0.84–0.86. For cirrhosis (F=4), the AUROC was reported to be in the 
range of 0.93–0.96. From this, one can conclude that TE is more reliable for diagnosing 
cirrhosis (the correct classification in 80–98% of the cases) than it is for significant 
fibrosis [21]. The chances of the correct staging of liver fibrosis using the over-the-
threshold measurement of liver stiffness (7.3kPa for F≥2 and 15kPa for F=4) are 92% 
and 72%, respectively. This means that this method is very reliable when used to rule 
in significant fibrosis but is not reliable for cirrhosis [18]. In other words, almost 30% of 
cases diagnosed as cirrhosis are actually false positive. On the other hand, the method 
is very reliable for ruling-out cirrhosis, with a very low number of false negative results 
(6%) following stiffness measurements with values below the established threshold. In 
contrast, TE is not reliable for ruling out significant fibrosis, with a very high number of 
false negative results (up to 45%). The cut-off values for certain stages of liver fibrosis 
differ depending on the aetiology and are not the same in viral hepatitis, non-alcoholic 
fatty liver disease, cholestatic liver diseases, etc. All these observations of the 
diagnostic performance of elastography for fibrosis-staging hold true for other 
elastography methods, i.e., pSWE and 2DSWE. In terms of diagnostic accuracy of 
2DSWE (by Supersonic Shear Imaging) recent meta-analysis of individual data 
revealed the following LSM cut-off values (AUROCs in parentheses): 7.1 kPa (0.86), 
9.2 kPa (0.91) and 13 kPa (0.93) for significant, advanced fibrosis and cirrhosis 
respectively, with an exemption for the patients with chronic hepatitis B in whom 
corresponding values of LSM (AUROC) were somewhat lower 7.1 kPa (0.91), 8.1 kPa 
(0.93) and 11.5 kPa (0.96) [22]. Reported optimal cut-off values (AUROCs) of LSM by 
pSWE as represented with ElastPQ were respectively 7.04 kPa (0.88) , 8.83 kPa (0.91) 
, and 9.11 kPa ( 0.91) [23]. 
 
4. 2.   Establishing the diagnosis of clinically relevant portal hypertension and high-
risk oesophageal varices 
Portal hypertension (PH) is an important complication of chronic liver disease and 
determines the clinical outcome of the disease [24]. Measuring the hepatic venous 
pressure gradient (HPVG) is an invasive method that is performed in a small number 
of hepatology centres. This is the reason why non-invasive methods for establishing 
the severity of PH are being researched. Complications of PH (oesophageal varices 
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(EV), ascites, encephalopathy) occur when the HVPG >10mmHg and this is 
considered to be a clinically significant portal hypertension (CSPV). Values of the 
HVPG from 6–10mmHg are considered subclinical PH [25]. A diagnosis of CSPH is 
usually established following endoscopically proven EV, or splenomegaly or 
portosystemic collateralization, as revealed by an abdominal US. Around 30% of 
patients with CSPH do not develop EV or other signs of CSPH, yet these are not 
excluded from the adverse clinical outcomes and, therefore, it is important to diagnose 
and manage PH in good time. Elastography can help in assessing the severity of PH. 
Studies have shown that a combined LSM and platelet count can reliably differentiate 
between patients with CSPH and high-risk oesophageal varices (HRV). Most data on 
this issue have been accumulated from studies on viral hepatitis, especially chronic 
hepatitis C. According to the Baveno VI consensus, CSPH may be assumed in patients 
with an LSM >20–25 kPa, whereas the combination of an LSM <20 kPa and a platelet 
count >150 000 may be used to safely rule out HRV [26]. By using these criteria, the 
risk of missing HRV is around 2% and 21% of endoscopies can be avoided, as 
revealed by the studies that followed [27]. The Baveno criteria were later extended to 
propose LSM<25kPa + platelet counts > 110x109/L, according to which, only 1.6% of 
cases with HRV are not recognized and 40% of gastroscopies have been avoided [28]. 
The spleen stiffness measurement (SSM) has recently been demonstrated as an 
independent predictor of HRV, with a cut-off value of ≤46 kPa that reliably excludes 
HRV. Combined with the Baveno VI criteria, an SSM algorithm was able to avoid 
endoscopy in 43.8% of patients with <5% risk of missing HRV [29]. Nevertheless, due 
to inconsistent results with the SSM reported in previous studies, these encouraging 
data should be further validated before any firm recommendations may be given [30].  
4.3.   Characterization of liver tumours 
Different types of liver tumours differ in their stiffness as the result of different 
histological structure. Most of the data accumulated to date have demonstrated that 
malignant tumours are stiffer than benign tumours. However, it should be noticed that 
various elastography methods have been used and the results were usually expressed 
as the mean stiffness of the whole tumour or its parts [31-33]. With the introduction of 
2DSWE, a more complex analysis of the tumour’s elastographic features has become 
possible, including the analysis of the ratio between the stiffness of the tumour and the 
surrounding liver parenchyma as well as the stiffness variability within the tumour. This 
is important since it appreciates the clinical background at which certain tumours arise. 
For instance, hepatocellular carcinoma (HCC) commonly develops in cirrhotic livers 
and both the tumour and the non-infiltrated liver may be assessed by elastography 
during the same examination [34]. By using this approach liver elastography 
malignancy prediction (LEMP) score has recently been proposed and it was able to 
differentiate between benign and malignant tumours in 96.1% of cases [35]. This 
algorithm overcomes the limitations of elastography when only mean tumour stiffness 
is used. For example, HCC and focal nodular hyperplasia (FNH) have comparable 
mean stiffness, yet, in most cases, the surrounding liver parenchyma in HCC patients 
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is stiff (cirrhotic), whereas in FNH patients it is soft (healthy). In addition, the 
heterogeneity of tumour stiffness is appreciated and is also incorporated into the LEMP 
formula. A more simplified approach uses only dichotomized values of mean tumour 
stiffness (14 and 32.5 kPa) with a 96% negative and positive predictive value for 
malignancy, which is applicable in 55.6% of the patients, whereas 44.4% remain in the 
“grey zone” between these cut-off points [35]. Although innovative, this elastographic 
approach to FLL is  time consuming, and should be validated in independent cohort.  
4.4. Prognosis of the clinical outcome for chronic liver disease 
It has been demonstrated that higher liver stiffness is accompanied by a worse 
prognosis [36]. Patients with LSM<9.5–10 kPa have a 4–5% chance of adverse clinical 
outcomes in the next three to five years [37,38]. For every 1 kPa above these values, 
the chance of an adverse outcome increases by 5% and patients with LSM >20 kPa 
have significantly diminished survival figures (positive predictive value 20%, negative 
predictive value 97%!). The prognostic predictive value of liver stiffness has also been 
confirmed with methods other than TE. In patients with compensated cirrhosis baseline 
LSM21.5 kPa by 2DSWE-SSI was associated with 3.4-fold (P=0.026) higher risk of 
liver-related events [39]. Longitudinal studies with repeated LSM have demonstrated 
worse clinical outcomes in patients with an increase in LSM by TE (>1kPa/year for 
patients with hepatitis C or >1.5  kPa for patients with primary sclerosing cholangitis) 
[40,41].  
 
5. Assessment of liver steatosis 
Different liver diseases are accompanied by the accumulation of fat in the liver but this 
is the most prominent histological feature of alcoholic and non-alcoholic fatty liver 
disease (NAFLD). NAFLD is becoming the leading cause of chronic liver disease with 
estimates of around 25% of the European population affected by this condition [42]. 
This disease is defined by the presence of more than 5% of fatty transformed 
hepatocytes [43]. Clinical impact of the severity (amount) of liver steatosis has been 
controvesial issue [44]. [45]. Whereas  higher grades of steatosis, as assessed non-
invasively by controlled attenuation parameter (CAP>220 dB/m), independently 
predicted worse clinical outcomes in patients with compensated advanced chronic liver 
disease (cACLD) of mixed aetiology in one study, the other study failed to demonstrate 
this association [46,47] Nevertheless, significant increase in the risk of cardiovascular 
events was reported in patients with higher grades of liver steatosis [48]. Therefore, 
knowledge of the severity of the liver steatosis appears to be clinically relevant. Grey 
scale US has insufficient sensibility to detect initial grades of liver steatosis but CAP 
can accomplish this during an elastographic assessment by Fibroscan device. CAP 
measures ultrasound attenuation at the central frequency simultaneously with the LSM 
and within the same region of interest [49]. According to the meta-analysis [8], the 
reported cut-off values of CAP (dB/m with the respective AUROCs) were 238 (0.82) 
for mild steatosis (S1, 5–33% fatty transformed hepatocytes), 259 (0.88) for moderate 
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steatosis (S2, 33–66% fatty transformed hepatocytes) and 290 (0.94) for severe 
steatosis (S3, >66%). With regard to the reliability criteria, the CAP IQR should be<40 
dB/m. In patients with a higher body mass index (especially BMI>30 kg/m2) and higher 
fibrosis stages (F3–4), CAP tends to overestimate the grade of the steatosis [50] and, 
vice versa, the fibrosis stage tends to be overestimated (high risk of false positive F2–
4)  at higher CAP values (>300 dB/m) [51]. Recently, a new method of acoustic 
structure quantification (ASQ) has been demonstrated to reliably quantify liver 
steatosis [9], but requires independent validation. This method is attractive since it has 
been incorporated into classical US machine and, therefore, avoids the need for a 
dedicated device.  
6. Contrast-enhanced ultrasound 
This method is based on the intravenous application of sulphur hexafluoride diluted in 
a saline solution that creates microbubbles smaller than red blood cells, which allows 
them to pass through the smallest blood vessels [52,53]. The phospholipid layer of the 
hexafluoride reflects US waves that are, in turn, captured by the US transducer to 
create an image of the investigated structure. This examination has to be performed 
using a low mechanical index of the US waves; otherwise, the microbubbles would be 
destroyed. The contrast is eliminated in 15 minutes through breathing, making it 
applicable even in patients with kidney dysfunction who cannot use the iodine contrast 
agents used for CT imaging. The application of sulphur hexafluoride is contraindicated 
in patients with unstable cardiopulmonary conditions, and not recommended during 
pregnancy or breastfeeding [54,55].  
Contrast-enhanced ultrasound (CEUS) is used for the characterization of focal liver 
lesions (FLL), especially liver tumours. The basic principle for this indication relies on 
the dual blood supply to the liver (around 70% of the blood volume provided by the 
portal vein and 30% by the hepatic artery). Following intravenous contrast injection, 
microbubbles enter the liver through the hepatic artery and then gradually through the 
portal vein. This temporal dynamics of contrast enhancement may be divided into three 
phases: the arterial phase (15–30 seconds after the contrast injection), the portal 
venous phase (30–120 seconds after the contrast injection) and the late phase that 
begins >120 seconds after the contrast injection [52]. By analysing the dynamics of the 
contrast flow and the time it takes for the contrast to leave the focal lesion, one can 
differentiate between benign and malignant FLL and even predict the histological type 
of tumour. The contrast is retained throughout the late phase in benign FLL, whereas 
it disappears (it is “washed-out”) from the malignant lesions during the venous or late 
phase.  The pattern of the contrast’s entrance and distribution during the arterial phase 
helps to predict the histological subtype of the lesion within the benign/malignant 
categories. For example, haemangioma have a characteristic peripheral nodular 
enhancement in the arterial phase with progressive centripetal filling, whereas in focal 
nodular, hyperplasia enhancement starts in the central part of the lesion with 
centrifugal progression. Both of these lesions retain the contrast and do not 
demonstrate the washout phenomenon. Hepatocellular carcinoma is rapidly and 
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completely enhanced in the arterial phase, which is followed by a more delayed 
washout, typically occurring in the late phase, whereas most metastatic tumours reveal 
rapid washout early in the portal venous phase. CEUS is highly accurate in 
differentiating malignant from benign lesions with sensitivity that exceeds 90% and 
specificity in the range of 83–90% [54-57]. Additionally, the presence of 
hyperenhancement in arterial phase followed by washout phenomenon has been used 
as reliable criterion to differentiate benign (blunt thrombosis) from malignant 
(infiltrative) portal vein thrombosis [58]. When CEUS was used to follow up patients 
resected for colorectal cancer, 151% more metastases were detected in 69% more 
patients as compared to the conventional B-mode US [59].  
CEUS has even been used to assess the severity of PH and this was based on the 
transit time of the US contrast through the liver. The best diagnostic performance for 
diagnosing severe PH (HVPG≥12 mmHg) was obtained using the intrahepatic transit 
time (ITT, cut-off value 6 sec, sensitivity 92%, specificity 89%, AUROC 0.94), which is 
the difference between the hepatic vein arrival time (HVAT) and hepatic artery arrival 
time (HAAT) [60]. Another approach relies on automated graph analysis of dynamic 
CEUS reflecting the degree of organization of the hepatic microvascular network that 
was reported in a pilot study to correlate to the severity of PH  in cirrhosis [61].  
 
7. Conclusion 
Ultrasound is a sophisticated point-of-care method that allows for very precise 
assessments of patients with liver disease using different modalities of US 
examinations, provided state-of-the-art equipment, qualified operators and patient’s 
body habitus that are adequate for the good visualization of the investigated structures. 
Under these conditions, US may be reliably used to assess the stage, complications 
and prognosis of patients with chronic and some acute liver diseases, as well as to 
characterize FLL. A simplified practical algorithms on the clinical use of MPUS in 
diffuse chronic liver diseases and FLL are proposed in Figures 2 and 3. Proper clinical 
use of US can shorten the duration of the diagnostic algorithm in liver diseases, as well 
as reduce the requirement for other, usually invasive and more expensive methods.  
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TABLES AND FIGURES 
 
Figure 1. Multiparametric ultrasound of a patients with compensated liver cirrhosis 
following successfull treatment of chronic hepatitis C, now under scheduled 6-month 
ultrasound (US) surveillance for hepatocellular carcinoma (HCC). A-typical  
morphological features of cirrhosis on greyscale US with coarse parenchyma and 
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irregular interface of hepatic veins; B-Small hypoechoc focal lesion (2.45 cm) on the 
surface of segment IV; C-Blood vessel  in the centre of the lesion was detected by 
power Doppler. Spectral analysis of the signal from the vessel revealed arterial flow; 
D-Portal vein was patent with normal hepatopedal direction of the blood flow, with 
decreased velocity (time averaged mean velocity, TAMV 9.9 cm/s); E-High liver 
stiffness (24 kPa) and F-high spleen stiffness (52 kPa) were measured by 2DSWE-SSI 
(in keeping with cirrhosis and clinically significant portal hypertension (CSPH); LSM by 
TE in the same patient was 23.1 kPa, Platelet count was 130x109/L and he had large 
oesophageal varices on endoscopy); G-Contrast enhanced ultrasound revealed 
hyperenhancement of the focal lesion in the arterial phase; H-incomplete wash-out of 
the contrast from the lesion in the portal-venous phase, and I-hypoenhancement 
(wash-out phenomenon) in the delayed phase, typical for HCC. All these US modalities 
were performed during the same visit, at the same US machine (Supersonic Aixplorer). 
Final conclusion based on MPUS examination was that patient had small HCC on the 
background of  compensated liver cirrhosis with CSPH. 
 
Figure 2.  Proposed simplified practical algorithm on the clinical use of multiparametric 
ultrasound in diffuse chronic liver disease. 
 
Figure 3.  Proposed simplified practical algorithm on the clinical use of multiparametric 






Table 1. Current methods of quantitative ultrasound elastography based on shear 
waves. ARFI=Acoustic Radiation Force Impulse, ElastPQ= Elastography Point 
Quantification; ElastQ=Elastography Quantification; SSI=Supersonic Shear Imaging; 
STE= Sound Touch Quantification;  STQ= Sound Touch Elastography; SWM=Shear 
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QUESTIONS AND ANSWERS (T=true; F=false) 
 
1. Single most accurate morphological sign of cirrhosis by greyscale 
ultrasound is: 
a) Hypertrophy of caudate lobe (F) 
b) Presence of ascites (F) 
c) Splenomegaly (F) 
d) Nodular liver surface/nodular interface of hepatic veins (T) 
e) Hyperechoic liver parenchyma (F) 
 
2. In patients with chronic liver diseases Doppler is best used to: 
a) Noninvasively assess the stage of liver fibrosis (F) 
b) Quantify the severity of portal hypertension (F) 
c) Assess the aetiology of portal hypertension (T) 
d) Assess the haemodynamic response of portal hypertension to drugs (F) 
e) Rule in the presence of high risk esophageal varices  (F) 
 
3. Elastography for noninvasive staging of liver fibrosis: 
a) Is best used to rule-out the presence of cirrhosis (T) 
b) Is best used to rule-out the presence of significant fibrosis (≥2) (F) 
c) Is best used to rule-in the presence of cirrhosis (F) 
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d) The results of liver stiffness measurements are interchangable when obtained 
by differents elastography methods (F) 
e) The results of liver stiffness measurements are not influenced by the 
histological  severity of the necroinflammation within the liver (F) 
 
4. Which of the following criteria used to rule-out the presence of high-risk 
esophageal varices by transient elastography may spare the highest 
number of unneccessary upper  gastrointestinal endoscopies: 
a) Liver stiffness<20 kPa (and  Platelets' count>150x109/L)  (F) 
b) Spleen stiffness<46 kPa (F) 
c) a+b (T) 
d) Liver stiffness<28 kPa (F) 
e) Liver stiffness<27kPa and Spleen stiffness<38 kPa (F) 
 
5. Which of the following statements is not true for contrast-enhanced 
ultrasound of the liver: 
a) It has excellent diagnostic performance to differentiate between benign and 
malignant focal liver lesions (T) 
b) Presence of wash-out phenomenon in the portal-venous or late phase is the 
hallmark of malignancy of focal liver lesions (T) 
c) It may be used to differentiate benign from malignant portal vein thrombosis 
(T) 
d) It is not recommended during pregnancy or breastfeeding (T) 
e) Should not be used in patients with chronic  renal failure (F) 
 
RESEARCH QUESTIONS 
 Clinical relevance of quantification  of liver steatosis by ultrasound methods 
 Diagnostic performance of ultrasound elastography methods other than 
transient elastography for grading portal hypertension and prognostication 
 Use of elastography to assess the haemodynamic response to medicamentous 
treatment of portal hypertension. 
 Use of contrast enhanced ultrasound to noninvasively quantify the severity of 
portal hypertension and its response to medicamentous treatment 
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